Here are six drug and medical device companies that made headlines in the past week.
1. Former Insys CEO to plead not guilty in opioid scheme indictment
John Kapoor, the billionaire founder and former CEO of Insys Pharmaceuticals, is expected to enter a not guilty plea Thursday over allegations he participated in a company scheme to bribe physicians to prescribe Insys' fentanyl-based painkiller Subsys.
2. FTC orders Abbott to divest 2 Alere medical devices after $8.3B acquisition
The Federal Trade Commission on Nov. 14 ordered Abbott Laboratories to divest two medical device product lines to settle a complaint that the company's $8.3 billion acquisition of Alere is anticompetitive.
3. Physio-Control recalls 14.2k defibrillator electrodes over packaging issues
Physio-Control, a Redmond, Wash.-based provider of external defibrillators and emergency medical response products, recalled about 14,200 electrodes due to packaging issues.
4. Acorda Therapeutics halts Parkinson's drug trials after 5 patient deaths
Acorda Therapeutics paused clinical trials of its Parkinson's disease drug, tozadenant, after reporting five patient deaths.
5. Bayer hires Nestlé head to combat Amazon effect in consumer health
Bayer, the Leverkusen, Germany-based drugmaker, tapped the head of Nestlé's baby food business, Heiko Schipper, to boost its consumer health revenue, which has been on the decline as buyers increasingly turn to online retailers like Amazon.
6. Mylan lays off up to 300 employees
Mylan Pharmaceuticals laid off between 200 and 300 employees in West Virginia Nov. 9.
More articles on supply chain:
Gartner names top 25 healthcare supply chains for 2017
4 ways the FDA is addressing the saline bag shortage
Acorda terminates Parkinson's drug development after patient deaths